TY - JOUR
T1 - Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung
AU - Assi, Hussein A.
AU - Padda, Sukhmani K.
N1 - Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Neuroendocrine tumors of the lung are a diverse group of diseases with distinct pathological, molecular, and clinical characteristics. The most recent World Health Organization (WHO) classification identifies two types of high-grade neuroendocrine carcinomas of the lung: small cell lung carcinoma (SCLC), and the less common large cell neuroendocrine carcinoma of the lung (LCNEC). Systemic treatments for these aggressive tumors have largely remained unchanged for years. With the advancement in genomic sequencing and identification of novel targetable pathways over the last decade, a myriad of therapeutic options have emerged, addressing unmet needs for this patient population. In this review, we summarize the latest advances in the management of SCLC and LCNEC, and discuss promising endeavors in development.
AB - Neuroendocrine tumors of the lung are a diverse group of diseases with distinct pathological, molecular, and clinical characteristics. The most recent World Health Organization (WHO) classification identifies two types of high-grade neuroendocrine carcinomas of the lung: small cell lung carcinoma (SCLC), and the less common large cell neuroendocrine carcinoma of the lung (LCNEC). Systemic treatments for these aggressive tumors have largely remained unchanged for years. With the advancement in genomic sequencing and identification of novel targetable pathways over the last decade, a myriad of therapeutic options have emerged, addressing unmet needs for this patient population. In this review, we summarize the latest advances in the management of SCLC and LCNEC, and discuss promising endeavors in development.
UR - http://www.scopus.com/inward/record.url?scp=85078813255&partnerID=8YFLogxK
U2 - 10.1016/j.ctarc.2020.100167
DO - 10.1016/j.ctarc.2020.100167
M3 - Article
C2 - 32007735
AN - SCOPUS:85078813255
SN - 2213-0896
VL - 23
SP - 100167
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
M1 - 100167
ER -